| April 3, 2014 | ISSUE NUMBER 345 VOL 4 |
Pricing
The Sovaldi Case: Is U.S. Biotech History About to Repeat Itself?
Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi — and a decline in stocks across the biotech sector — rings a familiar bell, writes Tom Norton ...Read more
Events
Musings from the Conference Circuit: A Wake-Up Call for Pharma
Bill Drummy reports on South by Southwest (SXSW) Interactive, the trendy, culture-fest that has grown enormously influential for the technology industry. It has also become, writes Drummy, arguably the hottest healthcare conference in the country
...Read more
White Paper – When Marketing for Adherence, Don't Ignore the Silent Majority
The importance of adherence is well recognized by industry, government, and a variety of healthcare experts. But motivating adherence is not always well understood. In this paper, inVentiv Health’s PMG shows how behavioral science, combined with online data and scientific evidence, can facilitate the behavior changes that can make a real difference to individual and public health. Read more
Marketing
Making the Most of Disruptive Technologies
Last week’s Digital Innovation Summit in Berlin offered plenty of insights into digital innovation, multiplatform content distribution and engaged audiences. Pharma marketers should be taking note, writes Peter Houston ...Read more
Global
“Market-Based” Price Controls in India?
Ram Subramanian, Nikhil Mutyal and Emma Nechamkin outline three strategic implications for pharma pricing strategies in India ...Read more
Event
Digital Summit Preview: Improving Brand Engagement
The upcoming digital marketing forum, iPharma2014 (May 8–9, New York City) will bring together more than 40 of the top minds to share fresh insights and innovative approaches in brand engagement and patient/physician interaction and relationship management ...Read more
Leadership
Pharm Exec’s Emerging Pharma Leaders 2014 — Nominate Now
It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself. ...Read more |
|
|
|
 //Immune Pharmaceuticals Inc. (New York, NY, and Herzliya, Israel) announced two senior members to its management team. Elliot Goldstein, MD, joined as Chief Medical Officer and Eugene Williams was named Chief Operating Officer.//Tonix Pharmaceuticals (New York, NY) announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Regulatory Affairs.//Chimerix, Inc. (Durham, NC), appointed Lisa Ricciardi to the Company's Board of Directors.//New Haven Pharmaceuticals, Inc. (Branford, CT), recruited Larry Dillaha, M.D., to the newly created position of Executive Vice President Operations.// |
|
|
|
|
|
